Evidence map›Paper›PMID 26204823›Full record

ArticleAnnals of hematology2015

Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia.

Olivia Geiger, Stefan Hatzl, Karl Kashofer, Gerald Hoefler, Albert Wölfler, Heinz Sill, Armin Zebisch

Open access · greenAbstract readLetter
In one paragraph

Article in Annals of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Role of SPRY4 in health and disease.Frontiers in oncology · 2024
    Review
  3. Article
  4. Article
  5. RASopathy Gene Mutations in Melanoma.The Journal of investigative dermatology · 2016
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Olivia GeigerDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Stefan HatzlDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Karl KashoferInstitute of Pathology, Medical University of Graz, Auenbruggerplatz 25, 8036, Graz, Austria.
Gerald HoeflerInstitute of Pathology, Medical University of Graz, Auenbruggerplatz 25, 8036, Graz, Austria.
Albert WölflerDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Heinz SillDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Armin ZebischDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria. armin.zebisch@medunigraz.at.
Medical University of Graz · AT

Funding

Austrian Science Fund FWF P 26619
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Disease ProgressionDNA Copy Number VariationsGene DeletionGene FrequencyHumansIntracellular Signaling Peptides and ProteinsLeukemia, Myeloid, AcuteNeoplasms, Second PrimaryNerve Tissue ProteinsRecurrenceIntracellular Signaling Peptides and ProteinsNerve Tissue ProteinsSPRY4 protein, human

Identifiers

PMID26204823
PMCPMC5024751
OpenAlexW969506957

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.